Related Experiment Video

Updated: Dec 5, 2025

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

27.8K

C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors

Milad Ashrafizadeh1, Ali Zarabi2, Kiavash Hushmandi3

  • 1Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Universite Caddesi No. 27, Orhanli, Tuzla, 34956 Istanbul, Turkey.

Current Cancer Drug Targets
|October 18, 2020
PubMed

Insights

The c-Myc oncogene pathway significantly impacts brain tumor development and progression. Understanding its mediators offers new therapeutic targets for treating brain cancers like glioma and glioblastoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Neuroscience

Background:

  • Brain tumors present significant global health challenges due to treatment resistance.
  • Conventional therapies are often ineffective against brain tumors, necessitating novel therapeutic strategies.
  • The blood-brain barrier (BBB) and tumor-specific biology complicate treatment approaches.

Purpose of the Study:

  • To review the role of the c-Myc oncogene pathway in brain tumors.
  • To identify upstream and downstream mediators of c-Myc in various brain tumor types.
  • To explore c-Myc's potential as a prognostic factor and therapeutic target.

Main Methods:

  • Literature review focusing on c-Myc signaling in brain tumors.
  • Analysis of c-Myc's regulatory roles in proliferation, apoptosis, and differentiation.
  • Investigation of c-Myc's involvement in glioma, glioblastoma, astrocytoma, and medulloblastoma.

Main Results:

  • c-Myc is a key regulator of critical cellular processes implicated in brain tumor growth.
  • Specific upstream and downstream mediators of c-Myc in brain tumors have been identified.
  • c-Myc signaling pathways are implicated across diverse primary brain tumor types.

Conclusions:

  • The c-Myc pathway is a crucial player in brain tumorigenesis and progression.
  • Targeting the c-Myc signaling axis presents a promising therapeutic avenue for brain tumors.
  • Further research into c-Myc mediators can guide the development of novel brain cancer treatments.
Keywords:
Brain tumorastrocytomac-Mycglioblastomagliomamedulloblastomasignaling pathway

More Related Videos

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

13.8K
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

16.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.4K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K